Plain-English translation of NCT06335979 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-stage trial is testing whether , a new injectable medication, is safe and effective for people with systemic lupus erythematosus (SLE). The study will gradually increase the dose of this treatment across different groups of participants to find the safest and most effective dose. Researchers will carefully monitor how your body responds to the medication and whether it helps control your lupus symptoms.
Standard lupus treatments don't work well enough for everyone, and some people continue to suffer from active disease despite taking current medications. This trial aims to see whether this new treatment could offer a better option for people like you whose lupus hasn't been controlled with conventional approaches.
You will receive injections of the medication under your skin, starting at a low dose and potentially increasing over time depending on how you respond and how safe the treatment is shown to be. The study starts with small groups of 3 participants who are closely monitored, and may expand once a safe dose is identified. You'll attend clinic visits for injections, blood tests, and check-ups to monitor your lupus activity and how your body is tolerating the medication.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
China
Germany
Hungary